## **Amendments to the Specification**

1) Please replace paragraph [0002] on page 1 with the following amended paragraph:

The invention was supported in part by Grant Nos.: made with U.S. government support under grants CA103823 (formerly AI16943), T32-CA62948, and AI051883 from awarded by the National Institutes of Health. The U.S. government may have has certain rights in this invention.

2) Please replace paragraph [0091] on page 36 with the following amended paragraph:

**Scheme 4.** Exemplary synthesis of the peptide backbone of the *N*-terminal fragment.

3) Please replace paragraph [0093] on page 37 with the following amended paragraph:

Scheme 5. Exemplary approach to the completion of the *N*-terminal fragment

Attorney Ref. No.: 2003080-0210 Client Ref. No.: SK-1156-US

4) Please replace paragraph [0095] on pages 37-38 with the following amended paragraph: **Scheme 6.** Exemplary synthesis of the *C*-terminal glycopeptide

5) Please replace paragraph [0116] on pages 45-46 with the following amended paragraph:

Scheme 10. Exemplary convergent coupling of functionalized glycopeptides.

- 6) Please replace paragraph [0120] on page 47 with the following amended paragraph:
- Scheme 11. Convergent coupling of two functionalized glycopeptides containing distinct, structurally complex glycans.<sup>a</sup>

Attorney Ref. No.: 2003080-0210 Client Ref. No.: SK-1156-US

7) Please replace paragraphs [0143] through [0147] on pages 52-54 with the following amended paragraphs:

The two glycopeptide halves (12, 2.2 mg, 1.44  $\mu$ mol) (18, 1.4 mg, 1.44  $\mu$ mol) were placed in a LCMS vial along with a flea-sized stirbar. A stock solution of MESNa (18.3 mg, 111 mmol) in phosphate buffered saline (0.2M NaCl, 0.2M phosphate, pH = 7.4, 1 mL) was made and of this, 600  $\mu$ L was added to the glycopeptides. The reaction was monitored by LCMS and, once finished, TCEP (25 mg, 0.087 mmol) was added and the solution stirred for 2 hr then injected directly onto the HPLC for purification.

LCMS: 5-65%B over 20 min, rt = 9.98 min. HPLC: 25-55%B over 30 min, rt = 7.65 min. ESI-MS: Calcd. for  $C_{93}H_{138}N_{24}O_{37}S$  [M+2H]<sup>2+</sup> 1108.5, Found: 1108.6, [M+3H]<sup>3+</sup> 739.3, Found: 739.5.

LCMS: 5-65%B over 20 min, rt = 11.40 min. HPLC: 5-65%B over 20 min, rt = 9.85 min. ESI-MS: Calcd. for  $C_{73}H_{120}N_{22}O_{30}S$  [M+2H]<sup>2+</sup> 909.4, Found: 909.5, [M+3H]<sup>3+</sup> 606.6, Found: 606.8.

LCMS: 5-65%B over 20 min, rt = 4.02 min. HPLC: 5-65%B over 20 min, rt = 6.71 min. ESI-MS: Calcd. for  $C_{73}H_{120}N_{22}O_{30}S$  [M+2H]<sup>2+</sup> 898.4, Found: 898.6.

LCMS: 5-65%B over 20 min, rt = 7.81 min. HPLC: 5-65%B over 20 min, rt = 8.39 min. ESI-MS: Calcd. for  $C_{98}H_{160}N_{24}O_{51}S$  [M+2H]<sup>2+</sup> 1261.5, Found: 1261.5, [M+3H]<sup>3+</sup> 841.4, Found: 841.5.

8) Please amend the specification on page 61 immediately following the references and immediately preceding the claims by inserting the Sequence Listing enclosed herewith.